Fiera Capital Corp Has $44.19 Million Stock Position in Insmed, Inc. (NASDAQ:INSM)

Key Points

• Fiera Capital Corp sold 2,617 shares of Insmed, Inc., lowering its holdings by 0.4%, leaving it with 579,237 shares valued at approximately $44.19 million.
• Notable insider sales include CFO Sara Bonstein offloading 58,400 shares at an average price of $102.67, reflecting a 44.27% decrease in her ownership.
• Insmed's stock opened at $101.75, with a current average price target from analysts of $109.20 and a consensus rating of "Moderate Buy."

Fiera Capital Corp cut its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 0.4% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 579,237 shares of the biopharmaceutical company's stock after selling 2,617 shares during the period. Fiera Capital Corp owned about 0.32% of Insmed worth $44,190,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cullen Frost Bankers Inc. grew its position in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 221 shares in the last quarter. Elequin Capital LP purchased a new position in Insmed during the fourth quarter valued at approximately $28,000. NBC Securities Inc. purchased a new position in Insmed during the first quarter valued at approximately $49,000. Versant Capital Management Inc grew its position in Insmed by 546.3% during the first quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 590 shares in the last quarter. Finally, Signaturefd LLC grew its position in Insmed by 60.0% during the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock valued at $66,000 after purchasing an additional 325 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on INSM. Royal Bank Of Canada lifted their target price on shares of Insmed from $99.00 to $106.00 and gave the company an "outperform" rating in a research note on Wednesday, June 11th. Leerink Partners lifted their target price on shares of Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a research note on Tuesday, June 10th. The Goldman Sachs Group lifted their target price on shares of Insmed from $100.00 to $112.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. Citigroup upgraded shares of Insmed to a "buy" rating in a research note on Tuesday, June 10th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Insmed from $90.00 to $111.00 and gave the company an "overweight" rating in a research note on Tuesday, July 8th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $109.20.

Insmed Stock Performance

Insmed stock traded up $0.47 during mid-day trading on Friday, reaching $107.75. The company had a trading volume of 1,304,799 shares, compared to its average volume of 2,755,710. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $108.64. The firm has a market cap of $20.44 billion, a price-to-earnings ratio of -18.12 and a beta of 0.90. The company has a quick ratio of 5.44, a current ratio of 5.86 and a debt-to-equity ratio of 11.38. The company has a 50 day moving average of $93.59 and a 200-day moving average of $80.77.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The business had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The business's revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.06) EPS. On average, sell-side analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, insider Michael Alexander Smith sold 933 shares of the company's stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $102.51, for a total value of $95,641.83. Following the sale, the insider owned 66,394 shares of the company's stock, valued at $6,806,048.94. The trade was a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the sale, the insider directly owned 89,407 shares in the company, valued at approximately $8,352,401.94. The trade was a 52.59% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 599,767 shares of company stock worth $54,625,108. Insiders own 3.00% of the company's stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.